- Scinai Immunotherapeutics expects to generate $2 million in CDMO revenue in 2025, with breakeven targeted by end of 2026.
- The company secured $1.38 million in new funding and will present strategic updates at BIO International Convention 2025.
Scinai Immunotherapeutics Ltd. has announced that CEO Amir Reichman will represent the company at the BIO International Convention 2025, to be held from 16–19 June in Boston. The event will serve as a platform to highlight Scinai’s recent operational, financial, and strategic milestones to prospective partners and investors.
The company recently secured $1.38 million in gross proceeds through a drawdown under its Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors. Executed at a 3% discount to market with no additional dilution mechanisms, the funding aims to support both the biologics CDMO business and R&D activities. Scinai is accelerating partner engagement to advance its nanobody pipeline toward IND-enabling studies while expanding CDMO capacity.
In its Q1 2025 financials, Scinai reported CDMO revenues that nearly matched its full-year 2024 figures, prompting the company to issue a 2025 revenue forecast of approximately $2 million. The CDMO unit is expected to reach breakeven by the end of 2026, with long-term annual revenue potential of $12 million under a single production shift.
To enhance financial stability, Scinai has initiated a cost-reduction programme projected to cut employment-related expenses by around $815,000 annually. The company noted that these reductions are designed to lower the burn rate without impacting its core operational capabilities.
“We’re heading into BIO with momentum on all fronts, new funding, commercial traction in our CDMO business, and focused execution across our R&D programs,” said Amir Reichman, CEO of Scinai.
Stay ahead of trends and best practices
